☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Marginal zone lymphoma
Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymp...
April 20, 2021
BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting
November 5, 2020
Celgene's Revlimid (Lenalidomide) + Rituximab Receive FDA's Approval for Previously Treated Follicular Lymphoma or Marginal Zone L...
May 29, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.